Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
Launched by SHANGHAI PULMONARY HOSPITAL, SHANGHAI, CHINA · Dec 29, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ERASE II study is a clinical trial that aims to understand the long-term effects of a treatment called Tobramycin Inhalation Solution on patients with bronchiectasis who have successfully eliminated a harmful bacteria known as Pseudomonas aeruginosa (PA). This study will follow participants for a total of 36 months to see how this successful treatment impacts their quality of life, lung health, frequency of lung infections, hospital visits, and overall costs of care. By building on earlier research, the trial hopes to provide valuable information about how eradicating PA can improve health outcomes over time.
To be eligible for this study, patients must have participated in the earlier ERASE study and be willing to sign a consent form. The trial is open to adults between the ages of 18 and 75, regardless of gender. Participants can expect regular check-ups over the study period, during which their health will be monitored closely. It’s important to note that individuals who were lost to follow-up in the previous study or deemed ineligible by the researchers will not be able to join this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients who participate the ERSE study
- • write the informed consent form.
- Exclusion Criteria:
- • patients who were lost of follow up in the ERASE study
- • ineligible for inclusion at the discretion of the researcher for other reasons.
About Shanghai Pulmonary Hospital, Shanghai, China
Shanghai Pulmonary Hospital, located in Shanghai, China, is a leading institution dedicated to the research and treatment of respiratory diseases. Renowned for its comprehensive clinical care and advanced research initiatives, the hospital specializes in pulmonary medicine and is committed to improving patient outcomes through innovative clinical trials. With a multidisciplinary team of experts and state-of-the-art facilities, Shanghai Pulmonary Hospital aims to contribute significantly to the global understanding and management of respiratory conditions, fostering advancements in therapeutic strategies and healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, , China
Jinan, Shandong, China
Shanghai, Shanghai, China
Nanning, Guangxi, China
Nanning, Guangxi, China
Shenyang, Liaoning, China
Wenzhou, Zhejiang, China
Shanghai, Shanghai, China
Zhengzhou, Henan, China
Suzhou, Jiangsu, China
Nanchang, Jiangxi, China
Hefei, Anhui, China
Chongqing, Chongqing, China
Nanchang, Jiangxi, China
Shanghai, Shanghai, China
Changchun, Jilin, China
Guiyang, Guizhou, China
Dalian, Liaoning, China
Nanjing, Jiangsu, China
Qingdao, Shandong, China
Guangzhou, Guangdong, China
Changsha, , China
Hangzhou, Zhejiang, China
Guangzhou, Guangdong, China
Beijing, Beijing, China
Changsha, Hunan, China
Huzhou, Zhejiang, China
Wuhan, Hubei, China
Shenzhen, Guangdong, China
Zhengzhou, Henan, China
Shenyang, Liaoning, China
Ningbo, Zhejiang, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Yangzhou, Jiangsu, China
Beijing, Beijing, China
Taiyuan, Shanxi, China
Shangrao, Jiangxi, China
Hefei, Anhui, China
Shanghai, Shanghai, China
Ningbo, Zhejiang, China
Shanghai, Shanghai, China
Kunming, Yunnan, China
Chongqing, Chongqing, China
Fuzhou, Fujiang, China
Shenzhen, Guangdong, China
Zhanjiang, Guangdong, China
Haikou, Hainan, China
Wuhan, Hubei, China
Nantong, Jiangsu, China
Nantong, Jiangsu, China
Suzhou, Jiangsu, China
Jinan, Shangdong, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Anning, Yunnan, China
Hangzhou, Zhejiang, China
Jiaxing, Zhejiang, China
Jiaxing, Zhejiang, China
Ningbo, Zhejiang, China
Patients applied
Trial Officials
Jin-Fu Xu, PhD
Principal Investigator
Huadong Hospital affiliated with Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported